Thyroid ResearchPub Date : 2023-06-12DOI: 10.1186/s13044-023-00158-4
Hawa Nuradin Mohamed, Abdi Karim Ahmed Ghedi, Sevgi Ozturk, Mohamed Osman Omar Jeele, Ahmed Muhammad Bashir
{"title":"Hypokalemic periodic paralysis as the first sign of thyrotoxicosis- a rare case report from Somalia.","authors":"Hawa Nuradin Mohamed, Abdi Karim Ahmed Ghedi, Sevgi Ozturk, Mohamed Osman Omar Jeele, Ahmed Muhammad Bashir","doi":"10.1186/s13044-023-00158-4","DOIUrl":"https://doi.org/10.1186/s13044-023-00158-4","url":null,"abstract":"<p><strong>Background: </strong>Thyrotoxic hypokalemic periodic paralysis (THPP) is a rare complication of hyperthyroidism characterized by thyrotoxicosis, hypokalemia, and paralysis. It is the most common form of acquired periodic paralysis. THPP is precipitated by strenuous exercise, a high carbohydrate diet, stress, infection, alcohol, albuterol, and corticosteroid therapy. It is most common in Asian men with hyperthyroidism and exceptionally rare in black people.</p><p><strong>Case presentation: </strong>A 29-year-old man was admitted to the emergency department in Somalia with a sudden onset of paralysis after a high carbohydrate meal. Laboratory investigations showed low serum potassium 1.8 mEq/l (3.5-4.5), and biochemical thyrotoxicosis with TSH 0.006 miu/l (0.35-5.1), total T3 3.2 ng/ml (0.9-2.8) and total T4 13.5 ng/ml (0.6-1.2). He was successfully treated with potassium chloride infusion and an antithyroid drug, methimazole.</p><p><strong>Conclusion: </strong>To prevent life-threatening cardiac and respiratory complications, it is critical to consider and diagnose THPP early, even in populations where the condition is rare.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"14"},"PeriodicalIF":2.2,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9618018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thyroid ResearchPub Date : 2023-06-12DOI: 10.1186/s13044-023-00154-8
Nanna Maria Uldall Torp, Inge Bülow Pedersen, Allan Carlé, Jesper Scott Karmisholt, Eva Ebbehøj, Diana Grove-Laugesen, Thomas Heiberg Brix, Steen Joop Bonnema, Bieke F Schrijvers, Birte Nygaard, Lena Bjergved Sigurd, Ulla Feldt-Rasmussen, Marianne Klose, Åse Krogh Rasmussen, Stig Andersen, Stine Linding Andersen
{"title":"Hyperthyroidism in pregnancy: design and methodology of a Danish multicenter study.","authors":"Nanna Maria Uldall Torp, Inge Bülow Pedersen, Allan Carlé, Jesper Scott Karmisholt, Eva Ebbehøj, Diana Grove-Laugesen, Thomas Heiberg Brix, Steen Joop Bonnema, Bieke F Schrijvers, Birte Nygaard, Lena Bjergved Sigurd, Ulla Feldt-Rasmussen, Marianne Klose, Åse Krogh Rasmussen, Stig Andersen, Stine Linding Andersen","doi":"10.1186/s13044-023-00154-8","DOIUrl":"https://doi.org/10.1186/s13044-023-00154-8","url":null,"abstract":"<p><strong>Background: </strong>Graves' disease (GD) is the main cause of hyperthyroidism in women of the fertile age. In pregnant women, the disease should be carefully managed and controlled to prevent maternal and fetal complications. Observational studies provide evidence of the adverse effects of untreated hyperthyroidism in pregnancy and have in more recent years substantiated a risk of teratogenic side effects with the use of antithyroid drugs (ATDs). These findings have challenged the clinical recommendations regarding the choice of treatment when patients become pregnant. To extend observational findings and support future clinical practice, a systematic collection of detailed clinical data in and around pregnancy is needed.</p><p><strong>Methods: </strong>With the aim of collecting clinical and biochemical data, a Danish multicenter study entitled 'Pregnancy Investigations on Thyroid Disease' (PRETHYR) was initiated in 2021. We here describe the design and methodology of the first study part of PRETHYR. This part focuses on maternal hyperthyroidism and recruits female patients in Denmark with a past or present diagnosis of GD, who become pregnant, as well as women who are treated with ATDs in the pregnancy, irrespective of the underlying etiology. The women are included during clinical management from endocrine hospital departments in Denmark, and study participation includes patient questionnaires in pregnancy and postpartum as well as review of medical records from the mother and the child.</p><p><strong>Results: </strong>Data collection was initiated on November 1, 2021 and covered all five Danish Regions from March 1, 2022. Consecutive study inclusion will continue, and we here report the first status of inclusion. As of November 1, 2022, a total of 62 women have been included in median pregnancy week 19 (interquartile range (IQR): 10-27) with a median maternal age of 31.4 years (IQR: 28.5-35.1). At inclusion, 26 women (41.9%) reported current use of thyroid medication; ATDs (n = 14), Levothyroxine (n = 12).</p><p><strong>Conclusion: </strong>This report describes a newly established systematic and nationwide collection of detailed clinical data on pregnant women with hyperthyroidism and their offspring. Considering the course and relatively low prevalence of GD in pregnant women, such nationwide design is essential to establish a sufficiently large cohort.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"11"},"PeriodicalIF":2.2,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9302852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Primary leiomyosarcoma of the thyroid with concurrent papillary thyroid cancer: a rare case report and a review of literature.","authors":"Mohamed Asiri, Faisal Alsarrani, Abdullah Altasan, Faisal Alqahtani, Lujain Akram Ali, Majed Pharaon, Saad Alshehri, Awad Alshahrani","doi":"10.1186/s13044-023-00157-5","DOIUrl":"https://doi.org/10.1186/s13044-023-00157-5","url":null,"abstract":"<p><strong>Background: </strong>Leiomyosarcoma (LMS) is a soft tissue malignant tumor that has a predilection to the abdominopelvic and limb smooth muscles. LMS of the thyroid is exceptionally rare. Papillary thyroid cancer (PTC) is the most common thyroid malignancy and originates from the thyroid epithelial layer. To our knowledge, the presence of both tumors in the same patient has not been reported previously.</p><p><strong>Case presentation & literature review: </strong>A 42-year-old woman presented with a progressively enlarging neck mass for a few months. She underwent left thyroid lobectomy, and the histology showed high-grade primary LMS of the thyroid. She subsequently underwent a complete thyroidectomy, which identified a classical PTC on her right lobe. Our comprehensive literature review identified 39 published cases of primary LMS of the thyroid. The average tumor size was 5.88 cm and occurred more in women. The most common presentation was neck mass, followed by compressive symptoms. Recurrence and metastasis were uncommon at 15% and 10-25%, respectively.</p><p><strong>Conclusion: </strong>Thyroid LMS is a rare malignancy with a worse prognosis than PTC. A thorough workup must be done to rule out metastasis before labeling it as primary thyroid cancer.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"16"},"PeriodicalIF":2.2,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9955577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effect of morning versus night-time administration of proton pump inhibitor (pantoprazole) on thyroid function test in levothyroxine-treated primary hypothyroidism: a prospective cross-over study.","authors":"Avivar Awasthi, Partha Pratim Chakraborty, Neeti Agrawal, Anirban Sinha, Anuj Kumar Pandey, Animesh Maiti","doi":"10.1186/s13044-023-00156-6","DOIUrl":"https://doi.org/10.1186/s13044-023-00156-6","url":null,"abstract":"<p><strong>Background: </strong>One of the common causes of suboptimal control of thyroid stimulating hormone (TSH) in levothyroxine-treated hypothyroidism is coadministration of proton pump inhibitors (PPIs). Morning administration of pantoprazole has been shown to suppress intragastric pH to a greater extent. We therefore aimed to determine the effect of pantoprazole at different time points of the day on thyroid function test (TFT) in levothyroxine-treated overt primary hypothyroidism.</p><p><strong>Methods: </strong>In this single centre, hospital based, prospective, two arm cross-over study (AB, BA), participants were randomized into 2 groups based on morning (6:00 am - 7:00 am simultaneously with the scheduled levothyroxine tablet) (group M) and evening (30 min before dinner) intake of 40 mg pantoprazole tablet (group N). After the initial 6 weeks (period 1), a washout period of 1 week for pantoprazole was given, and then both the groups crossed over for another 6 weeks (period 2). Patients were instructed to continue the same brand of levothyroxine tablet at empty stomach 1-hour before breakfast. Serum TSH was measured at baseline, week 6, and week 13.</p><p><strong>Results: </strong>Data from 30 patients, who completed the study with 100% compliance, were analysed. Mean TSH values of the study participants were significantly higher both at week 6 and week 13 compared to the baseline. Mean baseline serum TSH concentrations for groups M and N were 2.70 (± 1.36), and 2.20 (± 1.06) µlU/mL, respectively. Mean serum TSH concentrations at the end periods 1 and 2 for group M were 3.78 (± 4.29), and 3.76 (± 2.77) while the levels in group N were 3.30 (± 1.90), and 4.53 (± 4.590) µlU/mL, respectively. There was a significant rise in serum TSH concentration across periods 1 and 2 in both the groups (F<sub>2, 58</sub> = 3.87, p = 0.03). Within group changes in TSH across periods 1 and 2 were not statistically significant. Similarly difference in TSH between the groups, either at 6 weeks or at 13 weeks, were also not statistically significant.</p><p><strong>Conclusions: </strong>Concomitant use of pantoprazole, even for 6 weeks, leads to significant elevation in serum TSH in levothyroxine-treated patients who are biochemically euthyroid, irrespective of timing of pantoprazole intake. Early morning and night-time administration of pantoprazole have similar effect on TFT in these patients.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"15"},"PeriodicalIF":2.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9564755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thyroid ResearchPub Date : 2023-05-30DOI: 10.1186/s13044-023-00163-7
Peter N Taylor, Andrew Lansdown, Justyna Witczak, Rahim Khan, Aled Rees, Colin M Dayan, Onyebuchi Okosieme
{"title":"Correction to: Age-related variation in thyroid function - a narrative review highlighting important implications for research and clinical practice.","authors":"Peter N Taylor, Andrew Lansdown, Justyna Witczak, Rahim Khan, Aled Rees, Colin M Dayan, Onyebuchi Okosieme","doi":"10.1186/s13044-023-00163-7","DOIUrl":"https://doi.org/10.1186/s13044-023-00163-7","url":null,"abstract":"","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"20"},"PeriodicalIF":2.2,"publicationDate":"2023-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9908017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thyroid ResearchPub Date : 2023-05-15DOI: 10.1186/s13044-023-00153-9
Fatemeh Norouzi, Ismaeil Alizadeh, Maryam Faraji
{"title":"Human exposure to pesticides and thyroid cancer: a worldwide systematic review of the literatures.","authors":"Fatemeh Norouzi, Ismaeil Alizadeh, Maryam Faraji","doi":"10.1186/s13044-023-00153-9","DOIUrl":"https://doi.org/10.1186/s13044-023-00153-9","url":null,"abstract":"<p><p>Thyroid cancer is considered as one of the most prevalent cancers in the world. Some pesticides can play a role as a potentially important risk factor in thyroid cancer by affecting thyroid morphology and thyroid hormone homeostasis. The aim of present study was to systematically review the available epidemiological evidence for human exposure to pesticides and thyroid cancer. Articles were searched in PubMed, Scopus and Web of Science by suitable keywords from January 2000 to May 2021. Standard techniques for systematic reviews were followed in the current study and results reported according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Based on the inclusion and exclusion criteria, finally seven studies including four cohort studies and three case-control studies were reviewed. Organochlorines (OCPs) in more cases, Organophosphates (OPs) and Carbamates insecticides, herbicides and fungicides were the studied pesticides. Inconsistent results were reported in the surveyed articles on the OCPs. Two articles on the Carbamates (Carbaryl and Mancozeb) showed consistently an inverse association between exposure and thyroid cancer. Increased risk of thyroid cancer due to the exposure to the Malathion was reported in one article on the OPs. Due to the limited current knowledge about the effect of pesticides on thyroid cancer in humans, human health policies must be implemented to control individual's exposure to chemicals through using of botanical pesticides in agricultural. Also, more studies must be done to fill this gap of knowledge.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"13"},"PeriodicalIF":2.2,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9529388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thyroid ResearchPub Date : 2023-05-08DOI: 10.1186/s13044-023-00155-7
Ana Paula Borges, Célia Antunes, Filipe Caseiro-Alves, Paulo Donato
{"title":"Analysis of 665 thyroid nodules using both EU-TIRADS and ACR TI-RADS classification systems.","authors":"Ana Paula Borges, Célia Antunes, Filipe Caseiro-Alves, Paulo Donato","doi":"10.1186/s13044-023-00155-7","DOIUrl":"10.1186/s13044-023-00155-7","url":null,"abstract":"<p><strong>Background: </strong>Ultrasound-based classification systems allow stratification of thyroid nodules to recommend fine-needle aspiration (FNA) based on their malignancy risk. However, these have discrepancies that may have an impact in thyroid cancer detection. We aimed to compare European Thyroid Association (EU-TIRADS) and American College of Radiology (ACR TI-RADS), in terms of FNA indication and diagnostic performance.</p><p><strong>Methods: </strong>Retrospective study of 665 thyroid nodules from 598 patients who underwent ultrasound and fine-needle aspiration at a tertiary-care institution between January 1<sup>st</sup> of 2016 and July 31<sup>st</sup> of 2019. Based on their sonographic features they were classified according to the EU-TIRADS and ACR TI-RADS classification and then their cytological results were obtained. Differences in FNA indications according to these two classifications were analysed. In patients who underwent surgical removal of the nodules, the final pathological diagnosis was obtained.</p><p><strong>Results: </strong>A statistically significant association was found between EU-TIRADS and ACR TI-RADS classification systems (p < 0.001). ACR TI-RADS allowed greatest reduction in FNA performed (32% vs 24.5%). A different risk category was obtained in 174 (26.1%) nodules, mostly higher with EU-TIRADS. The indication to FNA changed in 54 (8.1%) nodules (49 only indicated following EU-TIRADS recommendations), of which 4 had Bethesda IV and 5 had Bethesda III cytology. The FNA indication in a higher number of nodules using EU-TIRADS was due to difference in the dimensional threshold for FNA on low-risk nodules; to the fact that hypoechogenicity in a mixed nodule ascribes it moderate risk, while using ACR TI-RADS it would only be considered of low risk, and to the use of isolated sonographic features, namely marked hypoechogenicity, microcalcifications and irregular margins, to automatically categorize a nodules as high risk in EU-TIRADS, while ACR TI-RADS requires a group of potentially suspicious features to consider a nodule of high risk. The analysis of pathology proven nodules revealed equally good sensitivity of both systems in the detection of malignancy, but weak specificity, slightly greater with ACR TI-RADS (27.1% vs 18.6%).</p><p><strong>Conclusions: </strong>The EU-TIRADS and ACR TI-RADS are both suitable to assess thyroid nodules and through risk stratification avoid unnecessary FNA. FNA was less performed using ACR TI-RADS, which was slightly more efficiency in excluding malignancy.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"12"},"PeriodicalIF":2.2,"publicationDate":"2023-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9439657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thyroid ResearchPub Date : 2023-05-08DOI: 10.1186/s13044-023-00159-3
Aqeeb Ur Rehman, Muhammad Ehsan, Haseeba Javed, Muhammad Zain Ameer, Aleenah Mohsin, Muhammad Aemaz Ur Rehman, Ahmad Nawaz, Zunaira Amjad, Fatima Ameer
{"title":"Correction to: Solitary and multiple thyroid nodules as predictors of malignancy: a systematic review and meta‑analysis.","authors":"Aqeeb Ur Rehman, Muhammad Ehsan, Haseeba Javed, Muhammad Zain Ameer, Aleenah Mohsin, Muhammad Aemaz Ur Rehman, Ahmad Nawaz, Zunaira Amjad, Fatima Ameer","doi":"10.1186/s13044-023-00159-3","DOIUrl":"https://doi.org/10.1186/s13044-023-00159-3","url":null,"abstract":"","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"17"},"PeriodicalIF":2.2,"publicationDate":"2023-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9443510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thyroid ResearchPub Date : 2023-05-01DOI: 10.1186/s13044-023-00152-w
Arne Heydorn, Birgitte Bertelsen, Rúna Louise Mortansdóttir Nolsöe, Pia Eiken, Peter Lommer Kristensen
{"title":"Thyrotoxic periodic paralysis in a Caucasian man without identifiable genetic predisposition: a case report.","authors":"Arne Heydorn, Birgitte Bertelsen, Rúna Louise Mortansdóttir Nolsöe, Pia Eiken, Peter Lommer Kristensen","doi":"10.1186/s13044-023-00152-w","DOIUrl":"https://doi.org/10.1186/s13044-023-00152-w","url":null,"abstract":"<p><strong>Background: </strong>Thyrotoxic periodic paralysis (TPP) is a rare condition characterized by muscle paralysis, thyrotoxicosis, and hypokalemia. It presents with paralysis of both proximal and distal musculature in upper and lower limbs and may affect respiratory musculature and the cardiac conduction system. Early diagnosis is essential, as the condition is potentially reversible by oral or intravenous potassium treatment, leading to rapid resolution without lasting weakness. Overlooking the diagnosis may result in respiratory failure and cardiac arrhythmias including QT prolongation, Torsades de points, and ventricular arrhythmias.</p><p><strong>Case presentation: </strong>A 19-year-old Caucasian man was admitted acutely with paralysis in upper and lower limbs and tachycardia. Over several months, he had experienced anxiousness, sweating more than usual, had daily palpitations, shortness of breath on exertion, and loose stools, and had lost 21 kg over the last year. Initial blood gas showed very low potassium of 1.4 mM, and blood tests showed decreased Thyroid-stimulating hormone (TSH) < 0.01 × 10<sup>- 3</sup> IU/L, elevated free thyroxine (fT4) of 63.5 pM (reference interval (RI): 12.0-22.0 pM), and elevated total triiodothyronine (T3) of 8.2 nM (RI: 1.0-2.6 nM). He was diagnosed with TPP and treated with liquid oral potassium chloride (30 mmol every 30 minutes) and propylthiouracil (initial dose of 400 mg followed by 200 mg three times daily). TSH-receptor antibodies (TRAB) and thyroid-peroxidase antibodies (TPO-ab) were highly elevated. Thyroid ultrasound showed a normal-sized gland and color Doppler sonography showed increased vascularity throughout the gland, compatible with Graves' disease. He was discharged on day 4 with a normal potassium level and followed in the outpatient clinic where he received standard care for Graves' disease. Genetic testing using whole-genome sequencing found no genetic variants in genes previously associated with TPP.</p><p><strong>Conclusion: </strong>TPP is very rare in Caucasians but more often affects young men in East Asian populations. The case presents a Caucasian man with TPP where genetic testing of CACNA1S, KCNJ18, SCN4A, KCNJ2, KCNE3, and ABCC8 shows no pathogenic variants in genes previously associated with TPP.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"10"},"PeriodicalIF":2.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9767939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thyroid ResearchPub Date : 2023-04-10DOI: 10.1186/s13044-023-00150-y
Syed Mohammad Asim Hussain, Suzanne Cole, Iram Hussain
{"title":"Colorectal cancer metastases in thyroid: case report and literature review.","authors":"Syed Mohammad Asim Hussain, Suzanne Cole, Iram Hussain","doi":"10.1186/s13044-023-00150-y","DOIUrl":"https://doi.org/10.1186/s13044-023-00150-y","url":null,"abstract":"<p><strong>Background: </strong>The thyroid gland is an uncommon site for metastatic deposits from non-thyroid malignancies, occurring in only 1.4 - 3% of surgical specimens where malignancy is suspected. It is even rarer for the source of thyroid metastases to be of colorectal origin. In most cases reported, colorectal metastases in the thyroid occurs many years later after the primary colorectal cancer has been diagnosed and treated. In this unique case, a primary sigmoid carcinoma metastasised to the thyroid gland and presented synchronously as a thyroid nodule.</p><p><strong>Case presentation: </strong>We describe a case of a 64-year-old Caucasian woman who presented with clinical features of metastatic cancer of unknown origin. Her medical history included underlying hyperthyroidism. She had a large pelvic mass adjacent to the sigmoid colon, a left lower lobe lung mass and a suspicious nodule in the left thyroid lobe. A fine-needle aspiration biopsy of the thyroid nodule was performed, which remarkably showed malignant cells originating from primary colorectal cancer on immunohistochemical staining. The patient was managed with palliative chemotherapy given the poor prognosis due to disseminated colorectal malignancy.</p><p><strong>Conclusions: </strong>Colorectal adenocarcinoma metastases can rarely present as a metastatic thyroid nodule. Fine-needle aspiration should be performed in suspicious thyroid nodules and may be the least invasive way of identifying a metastatic colorectal or other non-thyroidal malignancy in patients presenting with an unknown primary. The pathologist should be vigilant to this possibility and specific immunohistochemical markers should be used to ensure accurate diagnosis. In thyroid metastases, the prognosis is ultimately determined by the primary tumour but thyroidectomy still has a role in alleviating compressive symptoms and can potentially improve survival in selected cases.</p>","PeriodicalId":39048,"journal":{"name":"Thyroid Research","volume":"16 1","pages":"8"},"PeriodicalIF":2.2,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9275948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}